Trial Profile
A Phase I PK/PD Study of the PI3 Kinase/mTOR Inhibitor BEZ235 Given Twice Daily for the Treatment of Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Dactolisib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 27 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Jan 2014 Planned End Date changed from 1 Jan 2014 to 1 Mar 2014 as reported by ClinicalTrials.gov record.
- 23 Oct 2013 Results presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.